Background {#Sec1}
==========

Knee osteoarthritis (KOA) is a major public health problem in the middle-aged to elderly population that negatively affects patients' activities of daily living (ADL) and quality of life (QOL) \[[@CR1]--[@CR3]\]. Early diagnosis and treatment of KOA are required to prolong lifespan and reduce health care burden. Recently, the concept of early KOA has attracted attention in order to prevent disease development and progression \[[@CR4], [@CR5]\]. This concept is characterized by both the presence of knee symptoms and the absence of definitive radiographic abnormalities (Kellgren-Lawrence grades 0--1). Adults with KOA are more likely to report greater knee symptoms the year before they develop radiographic evidence of KOA \[[@CR6], [@CR7]\]. On the basis of these evidences, patients with early KOA may need to be targeted for therapeutic interventions as early as possible.

Pathologic changes found in osteoarthritic joints include degradation of the articular cartilage, thickening of the subchondral bone, osteophyte formation, varying degrees of synovial inflammation, degeneration of ligaments and menisci, and hypertrophy of the knee joint capsule \[[@CR8]\]. During the disease course, KOA is not only associated with cartilage degradation but also changes in bone tissue. A previous study evaluated subchondral bone marrow lesions (BMLs), detected by magnetic resonance imaging (MRI) among patients with KOA \[[@CR9]\]. More recent studies showed that the presence of BMLs is associated with knee pain and predicts cartilage loss in patients with established KOA \[[@CR10]--[@CR12]\]. Upon analysis of histological samples from end-stage KOA patients, BMLs indicated various pathologies, such as bone marrow necrosis, edema, fibrosis, trabecular abnormalities, and bony remodeling \[[@CR13]\]. In addition, antiresorptive drugs (e.g., bisphosphonate) were found to reduce the size of BMLs and the risk for total knee arthroplasty in KOA patients \[[@CR14], [@CR15]\]. BMLs reflect bony damage, which is associated with knee symptoms in KOA patients and changes its appearance according to bone metabolism such as bone absorption. Despite these pathological relationships among BMLs, bone abnormality, and bone metabolism in established KOA, little is known about how the condition of bone tissue correlates with the appearance of BMLs in early stages.

Bone mineral density (BMD) and bone markers are established tools for evaluating the condition of bone tissues, especially in osteoporosis. However, it remains controversial how BMD affects osteoarthritic changes of the knee joint. In fact, previous studies have reported that both low and high BMDs were associated with the precursors of cartilage degeneration or marginal osteophyte formation \[[@CR16]--[@CR18]\]. Additionally, although many biomechanical markers have been associated with KOA incidence and progression \[[@CR19], [@CR20]\], few reports clarify the relationship between bone markers and subchondral bone abnormalities in both established and early KOA patients. Moreover, limited data exist on the direct association among BMLs, BMD, and bone markers, especially in the context of early KOA. Therefore, this study aimed to clarify the cross-sectional association between BMLs, BMD, and serum bone markers in middle-aged women without radiographic features of KOA. Our hypothesis was that lower BMD is associated with symptomatic BMLs, owing to the fragility of subchondral bone and high turnover of bone metabolism.

Methods {#Sec2}
=======

The participants had previously volunteered for the Iwaki Health Promotion Project, which is a community-based preventative medicine program that aims to improve the average life expectancy by conducting general health checkups and prophylactic interventions, as previously described \[[@CR21]--[@CR23]\]. The Ethics Committee of the Hirosaki University Graduate School of Medicine approved the study (reference number: 2017-026), and all subjects gave written informed consent before participation.

A total of 1073 volunteers (441 men and 632 women) enrolled in the project in 2017. The participants answered questionnaires about their past and present medical history, lifestyle, occupation, family history, presence of menopause, health-related QOL, and disease-specific information such as knee symptoms. In this study, we focused on women without radiographic abnormalities because the prevalence of KOA is higher in women \[[@CR1], [@CR24]\]. Moreover, 441 men and 144 women who had radiographic features of KOA, 4 women who had undergone knee arthroplasty, 22 participants who did not receive radiography, and 196 women who lacked knee magnetic resonance images; had metal artifacts, a history of rheumatoid arthritis, or meniscus injury; or receiving some types of medications for osteoporosis were excluded. Finally, 266 women without radiographic abnormalities were included in the current analysis.

Knee symptoms were scored using a patient-based outcome score, the Knee injury and Osteoarthritis Outcome Score (KOOS). All participants completed the KOOS questionnaire independently. The KOOS questionnaire is a 42-item, knee-specific, self-administered questionnaire with 5 subscales: pain, symptoms, ADL, sports and recreation (sports), and knee-related QOL. All items were scored from 0 to 4 and then summed. Next, the raw scores were transformed to a 0--100 scale, with 100 representing the best result and 0 representing the worst \[[@CR25], [@CR26]\]. Participants were divided into symptomatic knee and asymptomatic knee groups on the basis of their KOOS: a knee was defined as symptomatic when the scores for 2 of the 4 KOOS subscales (except KOOS sports) were "positive" (below 85%), according to the established classification criteria for diagnosing early KOA \[[@CR5]\].

The presence of KOA was evaluated by weight-bearing and anterior-posterior radiographs of both knees. The beam was positioned parallel to the floor, with no angle, and aimed at the joint space. The severity of KOA was classified according to the Kellgren-Lawrence (KL) classification \[[@CR27]\]. A diagnosis of KOA was defined by KL grade ≥ 2 in the most affected knee. All joints were graded by two orthopedic surgeons (DC and ES), and any discrepancy was resolved by mutual consultation. As aforementioned, only the subjects who had no radiographic evidence of KOA were included in this analysis.

All participants underwent MRI of the right knee using a rapid extremity coil and mobile magnetic resonance unit (1.5 T; ECHELON RX, Hitachi, Tokyo, Japan) within 1 week after other examinations. The participants were positioned supine with their knees in full extension. Sequences included sagittal and coronal T2-weighted fat saturation fast spin echo (repetition time 5000 ms; echo time 80 ms; field of view 16 cm; 288 × 288 matrix; slice thickness of 3 mm with a between-slices gap of 1.0 mm). BMLs were defined as the area of an irregular hyperintense signal in the subchondral bone. The area was measured semi-quantitatively using the Whole-Organ MRI Scoring (WORMS) method \[[@CR28]\] in 15 subregions. Specifically, the medial and lateral compartments of the tibia and femur were divided into 3 subregions (anterior, central, and posterior), and the tibia had 1 additional subregion, representing the area beneath the tibial spine. The patella was divided into medial and lateral subregions (Fig. [1](#Fig1){ref-type="fig"}). BMLs were each scored as integers from 0 to 3, where 0 = normal; 1 = mild, \< 25% of the region; 2 = moderate, 25--50% of the region; and 3 = severe, \> 50% of the region (Fig. [2](#Fig2){ref-type="fig"}). The total BML score, which reflected severity, was calculated as the sum of the 15 subregional scores. BML was considered present if the total BML score was greater than zero. Two independent observers (DC and ES) scored MR images in a blinded fashion with no access to the participants' clinical information. The inter-rater reliability, expressed as interclass correlation coefficients \[ICC\] (2.1) of scoring BML on 100 randomly selected MR images, was 0.873 (95% confidence interval \[CI\] 0.815--0.914, *p* \< 0.001).Fig. 1Regional subdivision of the articular surfaces for the assessment of bone marrow lesions (BMLs). BMLs were assessed by the Whole-Organ MRI Scoring (WORMS) method. The patella, femur, and tibia were divided into medial (M) and lateral (L) regions. Region S represents the portion of the tibia beneath the tibial spines. The femoral and tibial surfaces were further subdivided into anterior (A), central (C), and posterior (P) regionsFig. 2Evaluation of bone marrow lesions (BMLs). BMLs were measured using the coronal and sagittal T2-weighted images and marked by the increased signal intensity area in the subchondral bone. BMLs were graded according to the percentage of the area according to the Whole-Organ MRI Scoring method. **a** Grade 1 BML in the anterior lateral femur. **b** Grade 2 BML in the posterior lateral femur. **c** Grade 3 BML in the posterior medial femur

The BMD of the forearm was determined by dual-energy X-ray absorptiometry using DCS-600EXV (Hitachi Aloka Medical, Tokyo, Japan). The region of interest of the BMD was measured on the non-dominant side at one-third of the distal radius, unless there was a history of previous fracture, in which case the dominant side was measured. Because this study was conducted as a part of a community-based general health check project in the limited space of a public hall, it was difficult to investigate the spinal or hip BMD, which needs a large facility to shield radioactive materials. Therefore, only the forearm was eligible for the measurement of systemic BMD.

Blood samples were taken from all participants before breakfast in the early morning for the determination of bone marker levels. Participants had a fasting restriction of 10 h or more before drawing the blood. We commissioned the LSI Medience Corporation to investigate the bone markers. This company has an ISO-15189-accredited laboratory, in which serum assays were performed under strict conditions. The serum levels of bone-alkaline phosphatase (BAP, μg/L, CLEIA; LSI Medience Corp., Tokyo, Japan) and type I procollagen N-terminal propeptides (PINP, μg/L, ECLIA; LSI Medience Corp., Tokyo, Japan) were measured for the assessment of bone formation \[[@CR29]\]. The serum cross-linked N-telopeptide of type I collagen (NTx, nM BCE/L, EIA; LSI Medience Corp., Tokyo, Japan) and tartrate-resistant acid phosphatase-5b (TRACP-5b, mU/dL, EIA; LSI Medience Corp., Tokyo, Japan) levels were measured to analyze the degree of bone turnover \[[@CR30]\]. In addition, pentosidine (pmol/mL, HPLC; LSI Medience Corp., Tokyo, Japan) and homocysteine (nmol/mL, LC-MS/MS; LSI Medience Corp., Tokyo, Japan) levels were evaluated to determine the degree of bone fragility \[[@CR31], [@CR32]\]. These bone markers are routinely used to evaluate the patient's bone turnover and bone quality and are recommended as the clinical references for diagnosing or treating osteoporosis as per the guidelines of Japanese Society for Bone and Mineral Research \[[@CR33]\]. The collected blood was distributed for refrigeration (samples for PINP and homocysteine) and freezing (samples for BAP, NTx, TRACP-5b, and pentosidine) for about 6 h (Hirosaki, Aomori). Next, the samples were sent to the laboratory (Itabashi, Tokyo) over the course of about half a day. During transport, serum samples for BAP, NTx, TRACP-5b, and pentosidine measurement were stored at − 20 °C and samples for PINP and homocysteine evaluation were stored at 7 °C. After arriving at the laboratory, the measurement started immediately, but it lasted for approximately 1 to 5 months; these samples were stored in controlled conditions under the aforementioned temperatures until the process of measurement was completed. Intra- and inter-assay precisions were 0.9--2.6% and 2.3--3.7%, 0.9--1.6% and 1.1--1.7%, 6.0--11.6% and 6.9--11.1%, 1.6--2.9% and 1.8--7.5%, 2.6--3.9% and 9.2--11.1%, and 1.9--3.9% and 2.6--4.5% for BAP, PINP, NTx, TRACP-5b, pentosidine, and homocysteine, respectively.

Data analysis was conducted using SPSS version 22.0 J (SPSS Inc., Chicago, IL, USA) in a cross-sectional manner. Normal distribution of the data was evaluated by QQ-plots and histograms. The mean values of continuous variables (age, body mass index (BMI), BMD, and bone markers) were compared using Student's *t* test, as these variables were normally distributed. Conversely, the median values of KOOS and BML score were compared using the Mann-Whitney *U* test, as these variables were not normally distributed. The chi-square test was used to compare the prevalence of symptomatic knees. To evaluate the relationship between BMLs and BMD, we performed multiple linear regression analyses with the BML score as an independent variable and age, BMI, and BMD as dependent variables. Moreover, to evaluate the relationship between BMLs and bone markers, we performed multiple linear regression analyses with the BML score as an independent variable and age, BMI, and bone markers as dependent variables. In addition, subgroup analyses were performed to determine whether there was a difference in the relationship between BMLs and BMD, and BMLs and bone markers, depending on the presence or absence of a symptomatic knee. For these regression analyses, natural log-transformed values of BML scores were used, as BML scores were not normally distributed. *p* values less than 0.05 were considered statistically significant.

Results {#Sec3}
=======

The mean age of study participants was 54.9 ± 9.6 years, mean BMI was 22.2 ± 3.3 kg/m^2^, and mean BMD was 0.60 ± 0.09 g/cm^2^, and 25.6% had symptomatic knee. Ninety-four participants (35.3%) had BMLs in the knee joint. The demographic features of participants with BMLs were higher age, lower KOOS, and lower BMD than those in participants without BMLs. Furthermore, the prevalence of a symptomatic knee among participants with BMLs was significantly higher than that among participants without BMLs (Table [1](#Tab1){ref-type="table"}). The mean BMD tended to decrease as the BML score increased (Fig. [3](#Fig3){ref-type="fig"}).Table 1Clinical characteristics of study participantsTotal sample (*n* = 266)With BMLs (*n* = 94)Without BMLs (*n* = 172)*p* valueAge, years54.9 ± 9.659.8 ± 7.352.3 ± 9.7\< 0.001BMI, kg/m^2^22.2 ± 3.322.3 ± 3.322.2 ± 3.30.886KOOS Symptom94.6 (85.7--100.0)92.9 (82.1--96.4)96.4 (89.3--100.0)0.006 Pain100.0 (88.9--100.0)95.8 (82.6--100.0)100.0 (88.9--100.0)0.013 ADL short ver.100.0 (92.9--100.0)100.0 (85.7--100.0)100.0 (96.4--100.0)0.037 QOL87.5 (73.4--100.0)81.3 (62.5--95.3)93.8 (75.0--100.0)0.004Symptomatic knee, *n* (%)68 (25.6)34 (36.2)34 (19.8)0.003BMD, g/cm^2^0.60 ± 0.090.55 ± 0.080.62 ± 0.09\< 0.001BML score0.0 (0.0--1.0)1.0 (1.0--2.0)0.0 (0.0--0.0)\< 0.001The values represent demographic data of all participants, participants with BMLs, and those without BMLs. Data are presented as mean ± SD for age, BMI, and BMD and median (range) for KOOS and BML score. The data on symptomatic knees is based on the number of participants (percentage of the whole population). Student's *t* test was used to compare the mean values of age, BMI, and BMD; Mann-Whitney *U* test was used to compare the median values of KOOS and BML score, and chi-square test was used to compare the proportions of symptomatic knees between participants with and without BMLs. *p* value indicates the significance of the difference between participants with and without BMLs*BMI* body mass index, *KOOS* Knee injury and Osteoarthritis Outcome Score, *BMD* bone mineral density, *BMLs* bone marrow lesionsFig. 3Mean value of BMD for each BML score. BMLs, bone marrow lesions; BMD, bone mineral density

According to the linear regression analysis, BMD was negatively associated with BML in all participants. However, the adjusted regression model showed that BMD was negatively associated with BML only in participants with a symptomatic knee after adjustment for age and BMI, and this association was attenuated and not statistically significant in participants with an asymptomatic knee (Table [2](#Tab2){ref-type="table"}).Table 2Relationship between BMLs and forearm BMD*R*^2^ (adjusted)*βp* value95% CITotal sample (*n* = 266)0.110− 0.1000.252− 0.517 to 0.137With asymptomatic knee (*n* = 198)0.071− 0.0110.918− 0.399 to 0.360With symptomatic knee (*n* = 68)0.222− 0.3550.014− 1.443 to − 0.167Statistical analysis---multiple linear regression analysis. Dependent variables---the natural logs of BML score plus 5. Independent variables---age, BMI, and BMD*BMLs* bone marrow lesions, *BMD* bone mineral density, *R*^*2*^ coefficient of determination, *β* standardized regression coefficient, *CI* confidence interval

Serum concentrations of BAP, PINP, NTx, TRACP-5b, and pentosidine were significantly higher in participants with BMLs than in those without BMLs. However, there was no significant difference in homocysteine levels (Table [3](#Tab3){ref-type="table"}). According to the linear regression analysis, BAP, PINP, NTx, and TRACP-5b were positively associated with BML in all participants. Although the adjusted regression model showed that these associations were attenuated, they were still statistically significant (Table [4](#Tab4){ref-type="table"}). In participants with asymptomatic knee, the adjusted regression model showed that BAP and TRACP-5b were significantly associated with BML (Table [5](#Tab5){ref-type="table"}). In participants with symptomatic knee, the adjusted regression model showed that BAP and PINP were significantly associated with BML, while the association between NTx and TRACP-5b was close to being significant (Table [6](#Tab6){ref-type="table"}).Table 3Laboratory characteristics of study participantsTotal sampleWith BMLs (*n* = 94)Without BMLs (*n* = 172)*p* valueBAP13.7 ± 5.015.6 ± 5.012.6 ± 4.6\< 0.001PINP49.2 ± 18.055.6 ± 18.945.8 ± 16.6\< 0.001NTx15.5 ± 5.016.7 ± 6.314.8 ± 4.10.002TRACP-5b442.2 ± 195.0523.2 ± 188.6397.8 ± 184.4\< 0.001Pentosidine29.2 ± 12.431.4 ± 17.328.1 ± 8.40.038Homocysteine8.5 ± 2.68.7 ± 2.58.4 ± 2.60.327Student's *t* test was used to compare the mean values of BAP, PINP, NTx, TRACP-5b, pentosidine, and homocysteine. *p* value indicates the significance of difference between participants with and without BMLs*BAP* bone-specific alkaline phosphatase, *BML* bone marrow lesion, *NTx* crosslinked N-telopeptide of type I collagen, *PINP* procollagen type I N-terminal propeptide, *TRACP-5b* tartrate-resistant acid phosphatase-5b, *BML* bone marrow lesionTable 4Relationships between BMLs and bone markersTotal sample (*n* = 266)*R*^2^ (adjusted)*βp* value95% CIBAP0.1350.1930.0030.002 to 0.011PINP0.1230.1420.0220.000 to 0.003NTx0.1210.1280.0320.000 to 0.009TRACP-5b0.1310.1940.0060.000 to 0.000Pentosidine0.1060.0110.852− 0.002 to 0.002Homocysteine0.106− 0.0220.708− 0.009 to 0.006Statistical analysis---multiple linear regression analysis. Dependent variables---the natural logs of BML score plus 5. Independent variables---age, BMI, and bone markers (BAP, PINP, NTx, TRACP-5b, pentosidine, and homocysteine)*BMLs* bone marrow lesions, *BAP* bone-specific alkaline phosphatase, *PINP* procollagen type I N-terminal propeptide, *NTx* crosslinked N-telopeptide of type I collagen, *TRACP-5b* tartrate-resistant acid phosphatase-5b, *R*^*2*^ coefficient of determination, *β* standardized regression coefficient, *CI* confidence intervalTable 5Relationships between BMLs and bone markers in participants with asymptomatic kneeWith asymptomatic knee (*n* = 198)*R*^2^ (adjusted)*βp* value95% CIBAP0.0910.1670.0380.000 to 0.010PINP0.0850.1310.0870.000 to 0.003NTx0.0750.0690.340− 0.003 to 0.008TRACP-5b0.1020.2280.0110.000 to 0.000Pentosidine0.0720.0360.623− 0.001 to 0.002Homocysteine0.071− 0.0230.742− 0.010 to 0.007Statistical analysis---multiple linear regression analysis. Dependent variables---the natural logs of BML score plus 5. Independent variables---age, BMI, and bone markers (BAP, PINP, NTx, TRACP-5b, pentosidine, and homocysteine)*BMLs* bone marrow lesions, *BAP* bone-specific alkaline phosphatase, *PINP* procollagen type I N-terminal propeptide, *NTx* crosslinked N-telopeptide of type I collagen, *TRACP-5b* tartrate-resistant acid phosphatase-5b, *R*^*2*^ coefficient of determination, *β* standardized regression coefficient, *CI* confidence intervalTable 6Relationships between BMLs and bone markers in participants with symptomatic kneeWith symptomatic knee (*n* = 68)*R*^2^ (adjusted)*βp* value95% CIBAP0.2390.3140.0060.004 to 0.024PINP0.1980.2310.0430.000 to 0.005NTx0.1890.2100.0650.000 to 0.013TRACP-5b0.1880.2250.0680.000 to 0.000Pentosidine0.151− 0.0840.482− 0.008 to 0.004Homocysteine0.152− 0.0930.440− 0.025 to 0.011Statistical analysis---multiple linear regression analysis. Dependent variables---the natural logs of BML score plus 5. Independent variables---age, BMI, and bone markers (BAP, PINP, NTx, TRACP-5b, pentosidine, and homocysteine)*BMLs* bone marrow lesions, *BAP* bone-specific alkaline phosphatase, *PINP* procollagen type I N-terminal propeptide, *NTx* crosslinked N-telopeptide of type I collagen, *TRACP-5b* tartrate-resistant acid phosphatase-5b, *R*^*2*^ coefficient of determination, *β* standardized regression coefficient, *CI* confidence interval

Discussion {#Sec4}
==========

This study evaluated the association between BMLs, BMD, and bone markers in middle-aged Japanese women with no radiographic evidence of KOA. We found that the prevalence of BML was 35%, and BML in the symptomatic knee was associated with a lower BMD, after adjusting for age and BMI. Furthermore, BAP, PINP, NTx, and TRACP-5b were positively associated with the presence of BML in all participants, while only BAP and PINP were positively associated with BML in participants with symptomatic knees.

Few studies have investigated the prevalence of BMLs specifically in a population without radiographic abnormalities. Laberge et al. reported that the prevalence of BML was 46.7% in a middle-aged population with knee symptoms but no radiographic evidence of KOA \[[@CR34]\]. Sowers et al. found that BMLs were identified in 40% knees of subjects without radiographic evidence of KOA \[[@CR35]\]. In this study, the prevalence of BML was 35% and slightly lower than that in previous reports. This may be because participants in this study had fewer knee symptoms compared to the participants of past reports.

The pathological association between KOA and BMD has remained controversial. Many previous studies have reported an association between high femoral BMD (weight-bearing) and KOA \[[@CR16], [@CR36]\]. However, another study indicated that high BMD decreased the risk of progression of radiographic KOA, but it may be associated with an increased risk of incident KOA \[[@CR37]\]. Moreover, one study suggested that the relationship between BMD and KOA varies depending on the site of OA and measurement of BMD \[[@CR18]\]. These results suggested that the relationship between BMD and KOA might differ depending on the disease stage of KOA (from early stage to end stage) and the presence or absence of loading on the measurement site of BMD. In this study, low BMD in the forearm (non-weight-bearing) and high bone marker levels were associated with BMLs. This finding suggests that systemic bone fragility may result in early subchondral changes such as microcracking before radiologic osteoarthritic findings become definitive. Laslett et al. reported that the size of BML shrinks due to the bisphosphonates used for osteoporosis treatment, resulting in improved pain \[[@CR14]\]. In addition, Zanetti et al. reported that the pathology of BML includes necrotic or remodeled trabeculae \[[@CR13]\]. Therefore, we believe in a possibility that bisphosphonate administration may be useful for BML before radiographic abnormalities become apparent.

There are many reports on the relationships between KOA and bone markers. Kumm et al. showed that PINP had a diagnostic and predictive value for knee OA progression \[[@CR38]\]. Nwosu et al. reported that serum TRACP-5b activity was associated with baseline pain and changes in pain over 3 years \[[@CR39]\]. Kraus et al. found that serum NTx levels were associated with subject cases that had both progressive pain and radiographic progression of knee OA over a 4-year period \[[@CR40]\]. On the other hand, only a few studies in addition to this study have investigated the association between BMLs and bone markers. Hunter et al. \[[@CR41]\] showed that serum NTx was weakly associated with the presence of BMLs, whereas Deveza et al. \[[@CR42]\] reported that serum CTX-I and urinary CTX-Ia levels were significantly associated with large BMLs. These results suggest an acceleration of bone turnover in KOA patients with BMLs. In this study, bone markers (BAP, PINP, NTx, and TRACP-5b) were positively associated with BMLs. Our results indicate that BMLs reflect enhanced bone remodeling to repair microfractures in the early stages of KOA. In particular, the correlation coefficient of BAP to BML was higher than that of other bone markers. There are a few studies reporting the relationship between BAP and KOA. BAP is one of the bone formation markers and reflects the activity of osteoblasts. A previous study found that the subchondral bone in osteoarthritic knee joints changed its phenotypic expression of osteoblasts \[[@CR43], [@CR44]\]. On the basis of the current results, the elevation in serum BAP concentration reflects that BMLs have a potential to activate osteoblasts in the subchondral bone of knee joints in the early stages of KOA.

Interestingly, in participants with an asymptomatic knee, there was no association between BMLs and BMD after adjustment for age and BMI, in contrast to that in participants with a symptomatic knee. A few reports have shown that early changes in the subchondral bone such as microcracking and periarticular osteoporosis occur before cartilage loss \[[@CR45], [@CR46]\]. Furthermore, several observational studies have explored knee pain and other symptoms as predictors of future radiographic KOA \[[@CR6], [@CR47], [@CR48]\]. In this study, because women with a symptomatic knee might be at a higher risk of cartilage loss and incidence of radiographic KOA, they showed a stronger relationship between BMD and BMLs than did women with an asymptomatic knee. These results indicate that future studies will need to determine the importance of maintaining systemic bone metabolism in women without radiographic abnormalities who have knee symptoms.

This study has several limitations. First, we did not evaluate BMD of the femoral neck and lumbar spine, which are considered the gold standards for diagnosing osteoporosis to determine fracture risk. This standard method needs cost, space, and frequent calibration to maintain its property. Because of these reasons, we could not evaluate the BMD of weight-bearing sites during the current study. Evaluation of forearm BMD determined the bone status of non-weight-bearing sites; this discrepancy could affect the current results. Second, all participants in this study were women. Although the prevalence of KOA is higher in women than in men, men may be more likely to experience a knee trauma, which may affect the prevalence of BMLs. Third, we did not evaluate knee alignment, which might affect the association of abnormal loading in the knee with the presence of BMLs. Fourth, because of the exploratory nature of this study, adjustments for multiple testing were not carried out. Therefore, these findings should be viewed as trends that need to be further investigated. Despite these limitations, this study shows the relationships between BML, BMD, and bone markers. In particular, BMD was negatively associated with BMLs, after adjustments for age and BMI, only in participants with symptomatic knees. The findings of this study were based on cross-sectional data; therefore, future longitudinal studies are warranted to investigate the causal relationship between BMD and BMLs. Furthermore, it is necessary to investigate whether BMLs resolve after treatment with antiresorptive drugs and whether the incidence and progression of KOA can be prevented in large observational studies.

Conclusion {#Sec5}
==========

A lower BMD was associated with the presence of BMLs in symptomatic knees, even if the knee was radiographically normal. In these knees, a high turnover of bone metabolism was related to the presence of BMLs.
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